Bolognesi R, Tsialtas D, Straneo U, Conti M, Manca C
Cattedra di Cardiologia, Università degli Studi di Parma.
Minerva Cardioangiol. 1990 Jun;38(6):299-303.
The availability of i.v. nicardipine has urged us to prove this drug in the treatment of hypertensive attacks (SAP greater than or equal to 210 mmHg and/or DAP greater than or equal to 110 mmHg). Two groups of patients (each made up of ten subjects) were treated with 2 mg and 5 mg respectively of i.v. nicardipine injected for 4 min while mean systolic and diastolic arterial pressure and heart rate were registered until three hours. I.V. nicardipine administration induced in both groups of patients a decrease in systolic pressure from 20 to 30% while diastolic arterial pressure decreased from 15 to 18% in the first group and from 20 to 25% in the second one. Heart rate showed an initial mild increase following arterial vasodilator action of nicardipine whereas it decreased significantly from 120 min in the presence of an unchanged hypotensive effect of the drug. One patient did not respond to nicardipine while another felt chest pain and palpitations. In conclusion our results are satisfactory and argue for the inclusion of nicardipine among the drugs that may be considered useful for the treatment of hypertensive attacks.
静脉注射尼卡地平的可得性促使我们对该药治疗高血压急症（收缩压≥210 mmHg和/或舒张压≥110 mmHg）进行验证。两组患者（每组由10名受试者组成）分别接受2 mg和5 mg静脉注射尼卡地平，注射4分钟，同时记录平均收缩压、舒张压和心率，持续观察3小时。静脉注射尼卡地平后，两组患者的收缩压均下降了20%至30%，第一组的舒张压下降了15%至18%，第二组下降了20%至25%。尼卡地平的动脉血管舒张作用使心率起初略有增加，而在药物降压效果不变的情况下，从120分钟起心率显著下降。1例患者对尼卡地平无反应，另1例患者出现胸痛和心悸。总之，我们的结果令人满意，支持将尼卡地平纳入可被认为对治疗高血压急症有用的药物之列。
